CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering […]
Intellia’s CRISPR/Cas9 proprietary process produces multiple, highly efficient sequential edits in T cells that have superior function and minimal translocations, […]